178 related articles for article (PubMed ID: 28939130)
21. Spontaneous antibody, and CD4 and CD8 T-cell responses against XAGE-1b (GAGED2a) in non-small cell lung cancer patients.
Ohue Y; Eikawa S; Okazaki N; Mizote Y; Isobe M; Uenaka A; Fukuda M; Old LJ; Oka M; Nakayama E
Int J Cancer; 2012 Sep; 131(5):E649-58. PubMed ID: 22109656
[TBL] [Abstract][Full Text] [Related]
22. [Expression of PD-1 and PD-L1 in the peripheral blood of advanced non-small-cell lung cancer patients and its implications].
Xing YF; Pan X; Qian B; Shi MH
Zhonghua Yi Xue Za Zhi; 2019 Jan; 99(2):111-114. PubMed ID: 30669748
[No Abstract] [Full Text] [Related]
23. Tumour islet Foxp3+ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer.
O'Callaghan DS; Rexhepaj E; Gately K; Coate L; Delaney D; O'Donnell DM; Kay E; O'Connell F; Gallagher WM; O'Byrne KJ
Eur Respir J; 2015 Dec; 46(6):1762-72. PubMed ID: 26541534
[TBL] [Abstract][Full Text] [Related]
24. Increased CD8+CD28+ T cells independently predict better early response to stereotactic ablative radiotherapy in patients with lung metastases from non-small cell lung cancer.
Liu C; Hu Q; Hu K; Su H; Shi F; Kong L; Zhu H; Yu J
J Transl Med; 2019 Apr; 17(1):120. PubMed ID: 30971280
[TBL] [Abstract][Full Text] [Related]
25. Impaired T-bet-pSTAT1α and perforin-mediated immune responses in the tumoral region of lung adenocarcinoma.
Andreev K; Trufa DI; Siegemund R; Rieker R; Hartmann A; Schmidt J; Sirbu H; Finotto S
Br J Cancer; 2015 Sep; 113(6):902-13. PubMed ID: 26348446
[TBL] [Abstract][Full Text] [Related]
26. [Progress in Immunotherapy for Squamous Non-small Cell Lung Cancer].
Wang S; Li J
Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):682-686. PubMed ID: 27760599
[TBL] [Abstract][Full Text] [Related]
27. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
Garon EB
Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
[TBL] [Abstract][Full Text] [Related]
28. Analysis of the immune microenvironment in resected non-small cell lung cancer: the prognostic value of different T lymphocyte markers.
Usó M; Jantus-Lewintre E; Bremnes RM; Calabuig S; Blasco A; Pastor E; Borreda I; Molina-Pinelo S; Paz-Ares L; Guijarro R; Martorell M; Forteza J; Camps C; Sirera R
Oncotarget; 2016 Aug; 7(33):52849-52861. PubMed ID: 27463005
[TBL] [Abstract][Full Text] [Related]
29. CD3+ CD4+ and CD3+ CD8+ lymphocyte subgroups and their surface receptors NKG2D and NKG2A in patients with non-small cell lung cancer.
Yu DP; Han Y; Zhao QY; Liu ZD
Asian Pac J Cancer Prev; 2014; 15(6):2685-8. PubMed ID: 24761885
[TBL] [Abstract][Full Text] [Related]
30. The prevalence of FOXP3+ regulatory T-cells in peripheral blood of patients with NSCLC.
Li L; Chao QG; Ping LZ; Xue C; Xia ZY; Qian D; Shi-ang H
Cancer Biother Radiopharm; 2009 Jun; 24(3):357-67. PubMed ID: 19538059
[TBL] [Abstract][Full Text] [Related]
31. Foxp3 expressing CD4+ CD25+ and CD8+CD28- T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma.
Meloni F; Morosini M; Solari N; Passadore I; Nascimbene C; Novo M; Ferrari M; Cosentino M; Marino F; Pozzi E; Fietta AM
Hum Immunol; 2006; 67(1-2):1-12. PubMed ID: 16698419
[TBL] [Abstract][Full Text] [Related]
32. MHC II lung cancer vaccines prime and boost tumor-specific CD4+ T cells that cross-react with multiple histologic subtypes of nonsmall cell lung cancer cells.
Srivastava MK; Bosch JJ; Wilson AL; Edelman MJ; Ostrand-Rosenberg S
Int J Cancer; 2010 Dec; 127(11):2612-21. PubMed ID: 20473949
[TBL] [Abstract][Full Text] [Related]
33. CD4
Kagamu H; Kitano S; Yamaguchi O; Yoshimura K; Horimoto K; Kitazawa M; Fukui K; Shiono A; Mouri A; Nishihara F; Miura Y; Hashimoto K; Murayama Y; Kaira K; Kobayashi K
Cancer Immunol Res; 2020 Mar; 8(3):334-344. PubMed ID: 31871122
[TBL] [Abstract][Full Text] [Related]
34. The role of tumor cells in the modification of T lymphocytes activity--the expression of the early CD69+, CD71+ and the late CD25+, CD26+, HLA/DR+ activation markers on T CD4+ and CD8+ cells in squamous cell laryngeal carcinoma. Part I.
Starska K; Głowacka E; Kulig A; Lewy-Trenda I; Bryś M; Lewkowicz P
Folia Histochem Cytobiol; 2011; 49(4):579-92. PubMed ID: 22252752
[TBL] [Abstract][Full Text] [Related]
35. Expression of activation-related molecules on regional lymph node lymphocytes in human lung cancer.
Takenoyama M; Yasumoto K; Harada M; Matsuzaki G; Ishida T; Sugimachi K; Nomoto K
Immunobiology; 1996 Jul; 195(2):140-51. PubMed ID: 8877391
[TBL] [Abstract][Full Text] [Related]
36. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer.
Kawai O; Ishii G; Kubota K; Murata Y; Naito Y; Mizuno T; Aokage K; Saijo N; Nishiwaki Y; Gemma A; Kudoh S; Ochiai A
Cancer; 2008 Sep; 113(6):1387-95. PubMed ID: 18671239
[TBL] [Abstract][Full Text] [Related]
37. Dysregulation of CD28 and CTLA-4 expression by CD4 T cells from previously immunodeficient HIV-infected patients with sustained virological responses to highly active antiretroviral therapy.
Stone SF; Price P; French MA
HIV Med; 2005 Jul; 6(4):278-83. PubMed ID: 16011533
[TBL] [Abstract][Full Text] [Related]
38. Variation of blood T lymphocyte subgroups in patients with non- small cell lung cancer.
Wang WJ; Tao Z; Gu W; Sun LH
Asian Pac J Cancer Prev; 2013; 14(8):4671-3. PubMed ID: 24083723
[TBL] [Abstract][Full Text] [Related]
39. CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients.
Djenidi F; Adam J; Goubar A; Durgeau A; Meurice G; de Montpréville V; Validire P; Besse B; Mami-Chouaib F
J Immunol; 2015 Apr; 194(7):3475-86. PubMed ID: 25725111
[TBL] [Abstract][Full Text] [Related]
40. CD25-expressing Th17 cells mediate CD8
Lang C; Wang J; Chen L
Exp Cell Res; 2017 Nov; 360(2):384-389. PubMed ID: 28942020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
